Answers are grounded in this paper and cite their sources.
Examines the effects of production duration on AAV capsid characteristics, suggesting important implications for gene therapy quality.
Adeno-associated virus (AAV) capsids are inherently heterogeneous, arising from viral protein stoichiometric assembly, post-translational modifications, genome packaging, and manufacturing process conditions. Understanding how AAV manufacturing processes affect capsid heterogeneity and corresponding drug product quality impact is essential for AAV-based gene therapies. We investigated the effects of extended production duration and capsid localization at harvest on capsid heterogeneity. Analytical characterization revealed that prolonged production increased extracellular AAV concentrations but also elevated the proportion of empty capsids, overall hydrophobicity, and deamidation of viral protein (VP). These changes altered charge-dependent separation during anion exchange chromatography (AEX). Capsids derived from intracellular fractions showed even higher levels of deamidation and empty particles compared to extracellular populations, further impacting AEX purification performance. Collectively, these findings demonstrate that both production time and capsid localization significantly influence AAV purification process performance and critical quality attributes. Process control strategies to minimize capsid heterogeneity are consequently critical to ensure a consistent quality profile in AAV manufacturing.
No takes yet. Share an insight, caveat, or question.
Meola et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: